In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Abiding Myth of Innovation

Executive Summary

The underlying theme of this year's Phoenix meeting was the need to carefully manage through times of rapid change and discontinuity and select appropriate corporate cultures. The medical device industry is, in large measure, built on the notion that small companies deliver the lion's share of innovative technology. But the critical role large companies play in bringing those products to market undermines, to a degree, the power small companies have as innovators. Thus, side by side with the value that innovative or disruptive technology brings is the power of incumbency and entrenched interests. And as the e-health revolution hits the skids, no segment better illustrates the ability of incumbency to take control over the discontinuity that disruptive technology brings than the Internet. There are, in fact, several reasons why even the most innovative devices fall short of being truly disruptive, including the long clinical and regulatory paths they must travel, the aversion most physicians have to products that make them change the way they practice medicine, and the critical role of big companies in marketing.

You may also be interested in...



MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities

Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel